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Bladderdysfunction(urinaryurgency/frequency),boweldysfunction(constipation),andsexualdysfunction(erectiledysfunction)
(also called “pelvic organ” dysfunctions) are common nonmotor disorders in Parkinson’s disease (PD). In contrast to motor
disorders, pelvic organ autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the
bladder dysfunction (appearance of overactivity) involves an altered dopamine-basal ganglia circuit, which normally suppresses
the micturition reﬂex. By contrast, peripheral myenteric pathology causing slowed colonic transit (loss of rectal contractions) and
central pathology causing weak strain and paradoxical anal sphincter contraction on defecation (PSD, also called as anismus) are
responsible for the bowel dysfunction. In addition, hypothalamic dysfunction is mostly responsible for the sexual dysfunction
(decrease in libido and erection) in PD, via altered dopamine-oxytocin pathways, which normally promote libido and erection.
The pathophysiology of the pelvic organ dysfunction in PD diﬀers from that in multiple system atrophy; therefore, it might aid
in diﬀerential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used
with caution particularly in elderly patients who have cognitive decline. Dietary ﬁbers, laxatives, and “prokinetic” drugs such as
serotonergic agonists are used to treat bowel dysfunction in PD. Phosphodiesterase inhibitors are used to treat sexual dysfunction
in PD. These treatments might be beneﬁcial in maximizing the patients’ quality of life.
1.Introduction
Parkinson’s disease (PD) is a common movement disorder
associatedwiththedegenerationofdopaminergicneuronsin
the substantia nigra. In addition to the movement disorder,
patients with PD often show nonmotor disorders. The non-
motor problems of PD include neuropsychiatric disorders,
sleep disorders, sensory symptoms, and autonomic disorders
[1]. Bladder, bowel, and sexual dysfunction (also called
“pelvic organ” dysfunctions) is one of the most common
autonomic disorders [2, 3]. Studies have shown that the
pelvic organ dysfunctions have great signiﬁcance in relation
to quality-of-life measures, early institutionalization, and
health economics [4, 5]. It is particularly important to note
that, unlike motor disorder, pelvic organ dysfunctions are
often nonresponsive to levodopa, suggesting that they occur
through a complex pathomechanism [6]. This is because
pathology of PD is not conﬁned to the degeneration of
dopaminergic neurons in the substantia nigra, and involves
other locations in the brain and other neurotransmitter
systems than the dopaminergic system. For this reason,
add-on therapy is required to maximize patients’ quality of
life. This article reviews pelvic organ dysfunctions in PD,
with particular reference to neural control of the bladder
[2], bowel [2], and genital organs, symptoms, objective
assessment, and treatment.
2. Bladder Dysfunction in PD
2.1. Neural Control of Micturition: Normal Micturition and
Detrusor Overactivity. The lower urinary tract (LUT) con-
sists of two major components, the bladder and urethra.2 Parkinson’s Disease
The bladder has abundant muscarinic M2, 3 receptors and
adrenergic beta 3 receptors, and is innervated by cholinergic
(parasympathetic) and noradrenergic (sympathetic) ﬁbers
for contraction and relaxation, respectively [7]. The urethra
has abundant adrenergic alpha 1A/D receptors and nicotinic
receptors, and is innervated by noradrenergic (sympathetic;
contraction) and cholinergic (somatic; contraction) ﬁbers
(Figure 1). The LUT performs two opposite functions,
storage and emptying of urine, both of which require an
intact neuraxis that involves almost all parts of the nervous
system[8].Thisisincontrasttoposturalhypotension,which
arises due to lesions below the medullary circulation center
in humans [9].
Normal urinary storage is dependent on the sacral
autonomic reﬂex [7, 10]. The storage reﬂex is thought to
be tonically facilitated by the brain, particularly the pontine
storage center [11, 12]. The pontine storage center lies just
ventrolateral to the pontine micturition center (PMC). In
addition to the pontine storage center, the storage function
is facilitated by the hypothalamus, cerebellum, basal ganglia,
and frontal cortex. These areas have been shown to be
activated during urinary storage by functional neuroimaging
in humans [13]. Normal micturition is dependent on the
spino-bulbo-spinal autonomic reﬂex [7], which particularly
involves the midbrain periaqueductal gray matter (PAG)
[14–17] and the PMC [7, 11]. The PAG is thought to
be central in regulating micturition and has a range of
inputs from the higher structures. The PMC is located
in or adjacent to the locus coeruleus [18–20]. The PMC
is thought to project spinal descending ﬁbers containing
glutamate as a facilitatory neurotransmitter, which activates
the sacral bladder preganglionic nucleus [21]. PMC also
projects ﬁbers containing γ-amino-butyric acid (GABA) and
glycineasinhibitoryneurotransmitters,whichsuppressesthe
sacral urethral motor nucleus (the Onuf’s nucleus) [22].
The voiding function seems to be initiated and facilitated by
the higher brain structures, for example, the hypothalamus
and prefrontal cortex, which seem to overlap in the storage-
facilitating area [13, 23]. Bladder (detrusor) overactivity
(DO) is the major cause of urinary urgency/frequency
and incontinence [24]. In lesions above the brainstem, the
micturition reﬂex arc is intact, where DO is considered an
exaggerated micturition reﬂex [24–26]. The exaggeration of
the micturition reﬂex might be brought about by more than
simply the decreased inhibition of the brain, and might be
further facilitated by glutamatergic and D2 dopaminergic
mechanisms [27].
2.2. Basal Ganglia Circuit and Dopamine. The net eﬀect of
the basal ganglia on micturition is thought to be inhibitory
(Figure 2)[ 7, 28–30]. Functional neuroimaging during
bladder ﬁlling results in activation in the globus pallidus of
normal volunteers [31] and in the putamen in patients with
PD [32]. In contrast, dopamine transporter imaging was
lower in PD patients with urinary dysfunction than in those
without it [33, 34]. Electrical stimulation of the substantia
nigra pars compacta (SNc) inhibited the micturition reﬂex
[35, 36], and striatal dopamine levels in situ signiﬁcantly
increased in the urinary storage phase in experimental
animals [37]. The micturition reﬂex is under the inﬂuences
of dopamine (both inhibitory in D1 and facilitatory in D2)
and GABA (inhibitory) [7, 28]. Both the SNc neuronal
ﬁring and the released striatal dopamine seem to activate the
dopamine D1-GABAergic direct pathway (Figure 2), which
notonlyinhibitsthebasalgangliaoutputnuclei,butalsomay
inhibit the micturition reﬂex via GABAergic collateral to the
micturition circuit [37–40]. In patients with PD, disruption
of this pathway may lead to DO and resultant urinary
urgency/frequency. In addition to the nigrostriatal ﬁbers,
the ventral tegmental area (VTA)-mesolimbic dopaminergic
ﬁbersarethoughttobeinvolvedinthecontrolofmicturition
[36, 41, 42]( Figure 1).
2.3. Bladder Dysfunction in PD
2.3.1. Lower Urinary Tract Symptom. The reported preva-
lence of LUT symptoms (LUTS) in patients with PD ranges
from 38% to 71% [43–48]. However, it has been diﬃcult
to determine to what extent PD contributes to LUTS.
Men older than 60 years of age may have bladder outlet
obstruction due to prostate hyperplasia. Women may have
stress urinary incontinence. “Idiopathic DO” [10]m a yo c c u r
in men and women older than 65 years due in part to latent
brain ischemia [49]. Some of the studies were published
before the diagnosis of multiple system atrophy (MSA)
[50] was recognized. In recent studies of PD patients who
were diagnosed according to modern criteria [5, 51–53],
the prevalence of LUTS was found to be 27–63.9% using
validated questionnaires [51–53], or 53% in men and 63%
in women using a nonvalidated questionnaire that includes
a urinary incontinence category [5], with all of these values
being signiﬁcantly higher than the incidence rates in healthy
controls. The majority of patients had onset of bladder
dysfunctionafterappearanceofmotordisorder.Correlations
have been shown between bladder dysfunction in patients
with PD and neurological disability [51], and bladder
dysfunction and stage of disease [5], both suggesting a
relationship between dopaminergic degeneration and LUTS.
However, Campos-Sousa and colleagues did not ﬁnd such a
correlation [53].
2.3.2. Storage Symptoms. LUTS are divided majorly into
two; storage symptoms and voiding symptoms. Storage
symptoms are the most common of the LUTS symptom
types in PD. Storage symptoms include nocturia (nighttime
urinary frequency), which is the most prevalent symptom
reported by patients with PD (>60%) [5, 51–53]. Patients
also complain of urinary urgency (33–54%) and daytime
frequency (16–36%). Urinary incontinence was present in
26% of male and 28% of female patients with PD [5].
2.3.3. Voiding Symptoms. Although less common than stor-
age symptoms, voiding symptoms also occur in PD patients.
In the study by Sakakibara and colleagues, PD patients
had signiﬁcantly higher rates of retardation in initiating
urination (44% of men only), prolongation/poor streamParkinson’s Disease 3
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Figure 1: Neural circuitry relevant to micturition. PAG, periaqueductal gray; LC, locus ceruleus; NBM, nucleus basalis Meynert; PVN,
paraventricular nucleus; MPOA, medial preoptic area; A, adrenergic/noradrenergic; ZI, zona incerta; VTA, ventral tegmental area; SNC,
substantia nigra pars compacta; DLTN, dorsolateral tegmental nucleus; PBN, parabrachial nucleus; IML, intermediolateral cell column;
GABA, γ-aminobutyric acid; T, thoracic; L, lumbar; S, sacral. See text.
(70% of men only), and straining (28% of women only)
compared with the control group [5]. Araki and colleagues
noted a correlation between voiding symptoms and stage of
disease [54]. However, despite the voiding symptoms, PD
patients have low postvoid residuals [5].
2.3.4. Videourodynamics, Pressure-Flow Analysis, and
Sphincter Electromyography
Bladder (Detrusor) Overactivity. The storage-phase urody-
namic abnormalities in PD include reduced bladder capacity
together with detrusor overactivity (DO) in 45–93% [43,
44, 54–58] of patients, and uninhibited external sphincter
relaxation in 33% [53] of patients (Figure 3). Therefore, DO
can be the major contributing factor to overactive bladder
in PD. There is also a correlation between DO and stage of
disease [55].
Mild, Weak Detrusor, and Sphincter Obstruction. Pressure-
ﬂow analysis [10, 59, 60] of the voiding phase in PD
has shown weak detrusor activity during voiding (40% of
men; 66% of women) [56]. There is a correlation between
a weak detrusor and the stage of the disease [55]. A
subset of PD patients had DO during storage but weak
detrusor activity in voiding. This combination has recently
been estimated to occur in 18% of patients with PD [61].
Some older studies described detrusor-external sphincter
dyssynergia or pseudodyssynergia in PD, and these ﬁndings
were attributed to PD by analogy with bradykinesia of the
limbs [62]. However, in our patients with PD, detrusor-
external sphincter dyssynergia was rare [56]. In contrast, a
pressure-ﬂow analysis in PD revealed that half of the patients
with PD showed mild urethral obstruction [56]. Patients
with PD are reported to have high resting urethral pressure,
probably as a result of medication—that is, levodopa and its
metabolites, such as norepinephrine. Irrespective of voiding4 Parkinson’s Disease
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Figure 2: Possible relationship between basal ganglia circuit (left side) and micturition circuit (right side; modiﬁed from Sakakibara et al.
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aminobutyric acid (GABA; inhibitory). The substantia nigra pars compacta (SNc) neuronal ﬁring and the released striatal dopamine seem
to activate the dopamine D1-GABAergic direct pathway, which not only inhibits the basal ganglia output nuclei (e.g., the globus pallidus
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Figure 3: Detrusor (bladder) overactivity by urodynamic measurement.Parkinson’s Disease 5
symptoms in PD, the average volume of postvoid residuals in
P Dw a sa ss m a l la s1 8m L[ 56].
Diﬀerential Diagnosis of Parkinsonism by Bladder Dysfunc-
tion. In the diﬀerential diagnosis of PD and parkinsonian-
type MSA, large postvoid residuals, open bladder neck, and
neurogenic change in sphincter motor unit potentials are
all common in MSA [56, 63] whereas they are rarely seen
in clinically typical PD. However, recent evidence suggests
that PD with dementia, or dementia with Lewy bodies [64],
may have large postvoid residuals and neurogenic change in
the sphincter motor unit potentials [65], thereby mimicking
MSA.
2.4. Treatment of Bladder Dysfunction in PD
2.4.1. Dopaminergic Drugs. It is possible that levodopa and
other antiparkinson medication may aﬀect bladder function
in PD. Aranda and Cramer [66] studied the eﬀects of 3–8mg
apomorphine injection on the storage function in 2 de novo
PD patients, and found that the bladder capacity increased.
They gave oral levodopa to one of the patients, and the
bladder capacity increased. We compared the frequency of
bladder dysfunction in de novo PD and PD with levodopa. In
that study, LUTS was less frequent than in the treated group
[59]. In another study, after 3 months of treatment with
levodopa, the storage urodynamic parameters were slightly
improved in de novo PD [67].
In contrast, in treated patients, studies concerning the
eﬀect of dopaminergic drugs on micturition have pro-
ducedconﬂictingresults.Regardingoveractivebladder,some
reports have shown a storage-facilitating eﬀect of dopamin-
ergicdrugs[5].Incontrast,Kunoandcolleaguesshowedthat
a change in medication from bromocriptine (D2 selective
agonist) to pergolide (D1 < 2 agonist) brought lessening of
nocturia[68],andYamamotodescribedimprovementofDO
by pergolide [69]. Benson and colleagues [70] gave 2000mg
of levodopa in 2 longstanding PD patients, and bladder
capacity increased in both patients. After discontinuation
of levodopa, the bladder capacity further increased in one
of the patients, but decreased in the other. Other reports
have shown a voiding-facilitating eﬀect of dopaminergic
drugs [71]. Fitzmaurice and colleagues [72]h a v ed e s c r i b e d
that, in advanced PD with the on-oﬀ phenomenon, DO
worsened with levodopa in some patients and lessened in
others. Winge and colleagues [73] found that the eﬀect on
micturition of treatment with dopaminergic drugs in PD
was unpredictable. Recent studies have shown that in early
PD [74] and advanced PD with the on-oﬀ phenomenon
[6], a single dose of levodopa exacerbates DO in the ﬁlling
phase. We still do not know the exact reasons for the
discrepancy.
There are several factors underlying the complex blad-
d e rb e h a v i o ri nt r e a t e dP Dp a t i e n t s[ 75]. Postsynaptic
dopamine D1 (excitatory) and D2 (inhibitory) receptors
have a millimolar aﬃnity to dopamine whereas dendritic
D2 (inhibitory) autoreceptors have a picomolar aﬃnity to
dopamine [76]. Therefore, levodopa may ﬁrst stimulate den-
dritic D2 autoreceptors, which might suppress the dopamin-
ergic cells and facilitate the micturition reﬂex. In cases of
PD under long-term treatment with levodopa, dopamine
receptors are downregulated and potential hypersensitivity
might occur [77]. The A11 dopaminergic cell group lies
in the dorsal-posterior hypothalamus, which is aﬀected in
marmosetswithMPTP-inducedparkinsonism [78].Thiscell
group descends as the sole source of spinal dopamine [79],
which might also involve in generating bladder overactivity
[80]. Peripheral dopamine D1 and D2 receptors also exist
in the bladder [81], although their exact role has not been
delineated.
2.4.2. Cholinergic Drugs. Anticholinergics [82]a r eg e n e r a l l y
usedasaﬁrst-linetreatmentforoveractivebladder.However,
it is important to balance the therapeutic beneﬁts of these
drugs with their potential adverse eﬀects. When the dose
of drug increases, postvoid residuals may appear [75]. Dry
mouthandconstipationarecommon[83].Cognitiveadverse
events by anticholinergics are a concern particularly in
the elderly. For example, trihexyphenidyl (for PD) and
oxybutynin(foroveractivebladder)havebeenshowntohave
central side eﬀects [84, 85]. Factors contributing to the cen-
tral eﬀects of drugs may include blood-brain barrier (BBB)
penetration [86]. Among the factors of BBB penetration,
diﬀusion is facilitated by lipophilicity [87]. Particularly in
elderly patients who have hallucinations or cognitive decline
(PD with dementia/dementia with Lewy bodies) [64, 65],
anticholinergics should be used with extreme caution.
2.4.3. Other Treatments. When a ﬁrst-line treatment fails or
is contraindicated, a second-line treatment might be consid-
ered. The main action of central 5-hydroxytryptamine- (5-
HT, or serotonin-) ergic neurons on the LUT is facilitation
of urine storage [88]. In PD, neuronal cell loss in the raphe
nucleus has been documented [89]. Therefore, serotonergic
drugs, such as duloxetine and milnacipran [90]c a nb ea
choice to treat overactive bladder in PD. Nocturnal polyuria
should be distinguished from overactive bladder. In patients
with PD, the imbalance between diurnal and nocturnal
production of urine can be observed in the course of
the disease [91]. Treatment with desmopressin proved to
be eﬀective in reducing nocturia in PD [92], although
this medication needs caution of water intoxication. The
subthalamic nucleus (STN) is regarded as the key area in
the indirect pathway, which is dominant in the parkinsonian
state [93]. Deep brain stimulation (DBS) in the STN inhibits
many cells within the STN, probably due to depolarization
block and release of GABA from activation of inhibitory
aﬀerent terminals [94]. In the STN, neuronal ﬁrings related
to the micturition cycle have been observed in cats [39].
DBS in the STN proved to have an inhibitory eﬀects on the
micturition reﬂex in animals [39, 40] and in patients with
PD [95–97]. DBS in the STN also increased bladder capacity
and facilitated bladder aﬀerent pathways in the brain of PD
patients [98, 99].6 Parkinson’s Disease
3.Bowel DysfunctioninPD
3.1. Neural Control of Defecation: Enteric Nervous System
and Dopamine. The enteric nervous system (ENS) plays
the most important role in regulating the peristaltic reﬂex
of the lower gastrointestinal (GI) tract (LGIT) [100]. Slow
phasic pressure waves are the most common manometric
phenomenon [101], and are measured in the colon and
rectum (spontaneous phasic rectal contraction) in humans
[102–105]. The origin of the slow wave rhythmicity in
LGIT has been identiﬁed in the myenteric (Auerbach’s) and
submucous (Meisner’s) plexuses, where interstitial cells of
Cajal (ICC) exist [106]. The peristaltic reﬂex consists of two
components: ascending contraction oral to, and descending
relaxation caudal to, the site of stimulus (Figure 4). The
reﬂex can be evoked by surface stroking or by circumfer-
ential stretch [100], in which 5-HT stimulates the sensory
nerve terminals [107]. The oral excitatory component is
mediated by cholinergic ﬁbers whereas the aboral inhibitory
component is mediated by nonadrenergic, noncholinergic
ﬁbers. Thus, local neuronal circuits and ICCs, together
with appropriate external stimuli, might bring about the
peristaltic reﬂex. Other types of pressure changes in the
colon include giant motor complexes [100],whichisperhaps
analogous to the migrating motor complex of small intestine
[100, 101]. After a meal, the motility index increases for
20 to 30min and remains elevated for up to 3 hours. A
combination of slow waves and giant motor complexes is
thought to promote bowel transport, which is measured by
colonic transit time (CTT) in humans [107, 108].
The strength of cholinergic transmission in the ENS is
thought to be regulated by opposing receptors; serotonin 5-
HT4receptor-mediating excitation [109,110]and dopamine
D2 receptor-mediating inhibition [111, 112]. Endogenous
5-HT may facilitate intestinal motility [109], as colorectal
motility is greater than normal in 5-HT transporter knock-
out mice with elevated extracellular 5-HT levels. Reports
using dopamine transporter knockout mice have indicated
that endogenous dopamine may inhibit intestinal motility
[113, 114]. However, a number of studies have also demon-
strated increased motility in the colon (scarce in dopamine
receptors) in response to dopamine [115, 116], presumably
mediated by other receptor populations such as adrenergic
or serotonergic receptors, or by central mechanisms [116]. It
is uncertain whether MPTP-induced parkinsonian animals
might have enteric dopaminergic pathology as seen in PD
[117–121]. Nevertheless, MPTP/salsolinol-induced parkin-
sonian animals showed decreased GI motility [122]a n d
decreased c-Kit expression in the ICC [123]. More recently,
Dorolet and colleagues found myenteric plexus alpha-
synuclein aggregate pathology, neuron loss, and slowing of
gastrointestinal motility in rotenone-induced parkinsonian
animals [124].
3.2. Extraenteric Nervous System and Dopamine. Whereas
small intestine and ascending colon are innervated by
the vagus nerves originating in the medulla, extraenteric
innervation of descending colon, sigmoid colon, and rectum
primarily shares that of the LUT (Figure 5)[ 7, 102]. LUT
and LGIT perform the similar function of storage and
emptying. However, there are also profound diﬀerences with
regard to physiology (dysfunctional transport, rare ureter
versus common bowel; smooth muscle contraction, only on
emptying bladder contraction versus persistent spontaneous
phasicrectalcontraction;abdominalstrain,minimumversus
large, resp.) [102]. In addition, while the LUT requires intact
neuraxis for storage and emptying [7], it has not been
entirely clear to what extent LGIT needs extra-ENS.
Acute transection of the pelvic plexus shows slowed
transit and abolishes the defecation reﬂex [125]. Six months
later, the transit and defecation reﬂex are recovered [125]. In
contrast, chronic replacement of esophagus [126]o rb l a d d e r
[127] by a colonic segment preserves colonic motility.
Pathological studies in PD have shown a degenerative lesion
in the spinal parasympathetic PGN [128], although the
degree is much less than that in MSA. No Lewy bodies were
found in the Onuf’s nucleus innervating the anal sphincter
[128]. Both the sacral cord and the vagus nuclei receive
projecting ﬁbers from Barrington’s nucleus (identical to
the PMC) in the pons. The spinal descending pathway for
defecation is located in the lateral columns in humans [129,
130].Intheacutestageofspinalcordinjury[131]ormultiple
sclerosis[132],CTTissigniﬁcantlyprolonged.Inthechronic
phase, prolonged CTT of the proximal colon returns to
normal whereas that of the distal colon persists [133, 134].
Abdominal strain and cough are accompanied by sphincter
contraction, which is called the guarding reﬂex [135].
However, when the sphincter contraction is large enough,
defecation becomes unsuccessful as commonly seen in spinal
cord injury (paradoxical sphincter contraction on defecation
(PSCD) or anismus) [136]. In the brainstem, lesion in the
vagusnucleicausesintestinal pseudo-obstruction [137,138].
In PD, neuronal cell loss [139] and the appearance of Lewy
bodies [128] in the vagus nuclei have been documented.
Barrington’s nucleus is thought to be critical to eliciting
migrating motor complex [140, 141]. In PD, involvement of
the Barrington’s nucleus has also been documented [139].
Thebasalgangliamodulatethebowelmotility[142,143],
with the main action apparently being inhibitory [142, 143].
However, under stress conditions, facilitatory responses were
also observed [144, 145]. Although the connection is not
fully clariﬁed, bowel function seems to be modulated by the
higher brain structures [146]. Most areas activated in func-
tional neuroimaging by bowel distention [147] strikingly
overlap the area activated by bladder distention [148].
3.3. Bowel Dysfunction in PD
3.3.1. Lower Gastrointestinal Tract Symptoms. In PD there is
dysfunctionalongtheentirelengthoftheGItract.Therefore,
while we focus on the colon and rectum, we refer to stomach
and small intestine when necessary. The reported prevalence
of LGIT symptoms in PD is mostly more than half [149–
151]. However, it has been diﬃcult to determine the extent
to which PD is contributing to the LGIT symptoms. This
diﬃculty occurs because not only PD but also idiopathic
constipation may occur in the elderly due in part to dietaryParkinson’s Disease 7
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habit [151], exercise [152], or age-related ENS degeneration
[153]. Controlled studies [5, 149, 154, 155]c o u l do v e r c o m e
these problems, in which the incidence rate of decreased
stool frequency (<3 times a week) in PD patients ranges
from 20% to 81%, that of diﬃculty in stool expulsion
in 57–67%, and that of diarrhea in 21%. All of these
values are signiﬁcantly higher than in the normal population
(range, decreased stool frequency, 0–33%; diﬃculty in stool
expulsion, 26–28%; diarrhea, 10%) [5, 149, 154, 155]. Fecal
incontinence has been reported to be 10–24% in PD [5,
149]. Therefore, constipation is the most prominent LGIT
symptoms in patients with PD. Indeed, PD is a risk factor for
elderlynursinghomeresidentstohaveconstipation[156].Of
particular importance is that bowel dysfunction aﬀects the
quality of life in patients with PD [5].
There is no signiﬁcant diﬀerence in the use of dopamin-
ergic or anticholinergic drugs and bowel dysfunction [5,
149].Diﬃcultyinexpulsion,anddiarrheaaremorecommon
in the higher grade of Hoehn and Yahr staging [5, 149, 150],
suggesting a relationship between dopaminergic degenera-
tion and LGIT symptoms. However, there are also studies in
which no such relationship was found [157]. Constipation
in PD occurs commonly with a low coeﬃcient of variation
in electrocardiographic R to R intervals [158]. The ﬁndings
indicate that parasympathetic dysfunction might underlie
these abnormalities. A recent epidemiological study revealed
an association between the frequency of bowel movements
and the future risk of developing PD [159]. From a clinical
perspective, it is of particular importance that patients
with PD see gastroenterologists or physicians ﬁrst because
of their bowel dysfunction before a diagnosis of PD is
made.
A more severe and often acute presentation of bowel dys-
function is intestinal pseudo-obstruction [160], also called
paralytic ileus. Yokoyama and Hasegawa [161] have recently
reported the frequency to be 7.1% among 112 patients with
PD.Radiographical featuresof intestinal pseudo-obstruction
are dilatation of colon and small intestine [160, 162–164].
True obstruction due to volvulus in PD also occur [161, 163,
164]. Intestinal pseudo-obstruction also occurs insidiously
[165, 166]. In such patients, histology specimens may reveal
Lewy body disorder.
3.3.2.LowerGastrointestinalTractFunctionTests. LGIT func-
tion primarily consists of (1) colonic transport of the bowel
content to the anorectum [107, 108], (2) transient anorec-
tum reservoir, and (3) defecation from the anorectum with
the aid of strain [102]. In PD, constipation results primarily
fromdecreasedtransportand/ordisturbedanorectalevacua-
tion. Fecal incontinence may result from disturbed anorectal
reservoir, or overﬂow secondary to constipation.
3.3.3. Transit Time Study. Previous reports have shown that
total CTT is increased beyond the normal threshold in 80%
of PD patients [167], which translates into an increased
average CTT ranging from 44 hours to 130 hours in PD
[167, 168], and in 89 hours in de novo PD patients [167],
all of which are signiﬁcantly longer than those of controls8 Parkinson’s Disease
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(range, 20–39 hours) [160, 167, 168]. Prolonged CTT has
also been documented in PD patients without subjective
constipation [169]. Slow colonic transit is the major cause of
decreased stool frequency. The slow colonic transit is likely
to reﬂect a decrease in slow waves and spike activities of the
colon, which may reﬂect the ENS pathology, and to a lesser
extent, the CNS pathology in PD. Among right, left, and
rectosigmoid segments of the CTT, the rectosigmoid CTT
is signiﬁcantly prolonged in PD patients [160, 167, 169].
Several explanations for this ﬁnding can be hypothesized.
It is possible that the ENS innervated by the sacral cord is
more severely aﬀected than that innervated by the DMV in
PD [160]. Oro-caecal transit time in PD is also prolonged
[170].
Pathological studies have demonstrated that PD aﬀects
the ENS [117–121]; showing decrease in dopaminergic
myenteric neurons and the appearance of Lewy bodies
along the proximal-distal axis, for example, they were
most frequent in the lower esophagus, but scarce in the
rectum. Presumably, degeneration of not only the inhibitory
(dopaminergic) ﬁbers, but also of facilitatory (cholinergic
and serotonergic) ﬁbers might contribute to the slow colonic
transit in PD.
3.3.4. Rectoanal Videomanometry and
Sphincter Electromyography
Resting State. Anal function at the resting state is measured
by anal manometry and analysis of the external sphincter
motor unit potentials. At the resting state, the anal pressure
of PD patients is low or normal [160, 171]. The resting anal
pressure may reﬂect sympathetic innervation in the internal
anal sphincter, since lesions or anaesthetic blocks at T12-L3
(where the sympathetic PGN is located) substantially lessen
the analpressure[172].Similarly, PDpatients havelow [173]
or normal [160, 171] anal pressure increase on squeezing.
However, neurogenic changes in motor unit potentials of
the external sphincter muscles occur in only 0–15% of PD
patients [174, 175]. This negative ﬁnding may correspond
to the result of pathological studies indicating that the sacral
Onuf’snucleusissparedinthemajorityofPDpatients[128].
Nevertheless, the latent anal sphincter dysfunction may
explain the fecal incontinence that occurs in most advanced
cases. The rectoanal inhibitory reﬂex comprises a slow anal
pressure decrease following a rapid distention of the intra-
rectal balloon [176]. This reﬂex might be appropriate for
evacuation. In PD, the threshold of the rectoanal inhibitoryParkinson’s Disease 9
reﬂex is reduced [168, 171, 177] or normal. Although this
reﬂex is thought to be mediated by the intrinsic ENS [178],
the exact reﬂex arc is not entirely clear.
3.3.5. Filling Phase. Rectoanal videomanometry measures
functionsoftheanorectumreservoirandevacuation.During
slow rectal ﬁlling, PD patients have a slightly but not
signiﬁcantly larger rectal volume at ﬁrst sensation and a
maximum desire to defecate compared with control subjects
[160, 171]. The PD patients had the same rectal compliance
as control subjects using the slow-liquid-ﬁlling method [102,
160], which is in accordance with the studies using the
balloon-inﬂation method. However, the amplitude of the
spontaneous phasic rectal contraction in the PD patients is
signiﬁcantly less than that in control subjects [102, 160]. The
decreased spontaneous phasic rectal contraction may share
the same aetiology with the decrease in CTT.
In normal subjects, anal pressure not only varies during
thestoragephase,butalsoshowsacloserelationwithsponta-
neous phasic rectal contraction, for example, when the rectal
pressure increases, the anal pressure tends to decrease [102].
The concurrent sphincter relaxation with the spontaneous
phasic rectal contraction resembles the rectoanal inhibitory
reﬂex [176]. The concurrent sphincter relaxation might
be appropriate for the following evacuation phase [102].
However, in the PD patients, both rectal and anal pressures
tend to increase together [160]. This phenomenon during
ﬁlling resembles the paradoxical sphincter contraction on
defecation, as described below.
3.3.6. Defecation Phase. In addition to slow transit consti-
pation, anorectal (outlet type) constipation is a common
feature in PD. Indeed, most PD patients could not defecate
completely and had postdefecation residuals, the volume
of which were signiﬁcantly larger than those in a control
group [160]. During defecation, it has remained a subject
of controversy whether true rectal contraction occurs, since
abdominal strain is large enough to mask the rectal con-
traction if present. Only a few studies have measured the
diﬀerential rectal pressure component [179] and not found
rectal contraction on defecation. In recent studies, healthy
c o n t r o ls u b j e c t sh a dam o d e r a t er e c t a lp r e s s u r ei n c r e a s eo n
defecation, for example, the healthy subjects utilized the
ﬁnal wave of spontaneous phasic rectal contractions for
defecation [102]. However, rectal contraction on defecation
in PD patients is smaller than that in controls [160].
The abdominal straining in PD patients is less than that
in control subjects [160]. Straining plays a physiological
role in both coughing and defecation, which is achieved by
cocontraction of the glottis, diaphragm, and abdominal wall
[180]. Straining is associated with activation in brainstem
nuclei such as the Kolliker-Fuse nucleus and medullary
respiratory neurons [180]. However, PD patients show a less
pronounced increase in abdominal pressure on coughing
[160, 181] and Valsalva maneuver [160, 182] before starting
rectal ﬁlling, and in the defecation phase [160, 182], than do
control subjects. The mechanism of the impaired straining
in PD may include rigidity and reduced contractility of the
axial muscles, and a failure of coordinated glottis closure
[181]. However, neuronal degeneration in the CNS relevant
to straining is yet to be clariﬁed in PD.
During defecation, the anal pressure increase on defe-
cation in patients is signiﬁcantly larger than that in control
subjects, with an increase in the sphincter electromyography
(EMG) activity. This ﬁnding in PD has been described as
paradoxical sphincter contraction on defecation (PSCD),
or anismus [118, 160, 167, 171, 182, 183]. During ﬁctive
defecation (straining), a lack of anal inhibition has also been
reported in 65% of PD patients. Although PSCD can also
be seen in patients with idiopathic constipation [184], the
frequent occurrence of PSCD in PD suggests that PSCD
is a disease-related condition. The frequency of PSCD is
almost the same in early and late PD [185], indicating
that PSCD is an early defecatory abnormality. Mathers and
colleagues [182] consider PSCD a focal dystonia. PSCD also
occurs in spinal cord-injured patients [136], suggesting that
dysfunction in the suprasacral descending pathway to the
external sphincter is a contributing factor. Apomorphine
is shown to lessen PSCD [182, 183]. This eﬀect was not
antagonized by domperidone, which did not penetrate the
BBB, suggesting that the CNS pathology may produce PSCD.
Both weak abdominal strain and PSCD seem to be the major
causes of diﬃculty in stool expulsion in PD patients.
3.4. Treatment of Bowel Dysfunction in PD
3.4.1. Dietary Fibers. Although it is not certain whether
exercise may facilitate bowel habit in PD, in the healthy
population, moderate exercise is reported to shorten mouth-
to-anus transit time [186] and improve overall wellbeing
[152]. Water content is an important determinant to make
stools normal (70% water) or hard (40–60% water) [184].
PD patients are reported to have reduced water intake
[187]. Diet and laxatives are the ﬁrst-line treatment for
constipation [188]. Dietary ﬁbers such as psyllium produced
an improvement in stool consistency and an increase in
stool frequency in healthy population [189]a n dP D[ 169,
190]. Polyethylene glycol 3350 [191], or bulking and highly
hydrophilic agent polycarbophil [192], improve constipation
in PD.
3.4.2. Cholinergic Drugs. A prior report has shown that
pyridostigmine bromide, an acetylcholinesterase inhibitor, is
eﬀective in the amelioration of constipation in PD [193].
3.4.3. Dopaminergic Drugs
Levodopa and Other Dopaminergic Agonists. Dopamine is
used as a peripheral vasoactive drug in intensive care units,
in which dopamine is shown to reduce gastric migrating
motor complex [194]. Dopamine also decreases gastric
motility in normal volunteers [195] whereas it increases
motility of the duodenum and sigmoid colon. Similarly,
dopamine administration increases colonic motor activity in
irritable bowel syndrome [196]. Unlike dopamine, levodopa
penetrates the BBB [197]. However, it is possible that10 Parkinson’s Disease
levodopa acts on the ENS and aﬀe c t sb o w e lf u n c t i o ni nP D ,
since levodopa can also be metabolized in the periphery.
A modern formula utilizes levodopa in combination with
peripheraldopa-decarboxylaseinhibitor. Thisregimencould
possibly reduce GI side eﬀects [198]. However, no reports
are available to see whether levodopa might change gut
function in untreated PD patients. As for somatic sphincter
function, levodopa improves voluntary anal squeezing in
ﬂuctuating PD patients, which parallels an improvement
in gait diﬃculty from “oﬀ” to “on” stage [177]. Apomor-
phine, a dopaminergic agonist, has also been shown to
lessen PSCD [182, 183]. This eﬀect is not antagonized by
domperidone,suggestingthatapomorphinemightactonthe
CNS dopaminergic pathways.
3.4.4. Dopaminergic Blockers. Dopaminergic blockers (dom-
peridone, etc.) are widely used as GI prokinetics by means
of antagonizing dopamine’s inhibitory eﬀects on the GI
motility, particularly D2 receptor blockade [199]. The
pharmacological proﬁles of the compounds diﬀer in terms
of their molecular structure, aﬃnity at D2 receptors, and
ability to interact with other receptor systems (5-HT3 and
5-HT4 receptors for metoclopramide; 5-HT4 receptors for
levosulpiride). Since domperidone does not cross the BBB,
it can be used as GI prokinetics for constipation in PD
[200], although the eﬀect of domperidone on constipation
is minimal. In contrast, dopaminergic blockers that could
penetrate the BBB (metoclopramide, levosulpiride, etc.)
may potentially worsen extrapyramidal motor disorder in
PD [199]. Since levodopa is absorbed from the small
intestine [201], bowel dysfunction in PD may interfere with
levodopa absorption, worsen the motor disorder, or even
lead to malignant syndrome [202, 203]. Gastric emptying
of an isotope-labeled solid meal becomes signiﬁcantly faster
during domperidone therapy in PD [200]. In addition,
domperidone pretreatment causes a mean 12% increase in
peak plasma levodopa concentrations that occurs a mean of
10min earlier than when levodopa is given alone [202]. Peak
plasmalevodopaconcentrationsarereportedtobegreateron
levodopa-domperidone than on levodopa-carbidopa [204].
3.4.5. Serotonergic Drugs. Cisapride, a selective 5-HT 4
receptor agonist, has signiﬁcantly shortened CTT in PD
[205], although after 1 year, only a small eﬀect could be
demonstrated [206]. Of particular importance is that cis-
apride add-on therapy improved the “on-oﬀ” phenomenon
in advanced PD [203]. However, some reports indicated
cisapride’s D2 dopaminergic receptor blocking property
[207]. Cisapride also blocks K+ channels and leads to
cardiotoxicity. Mosapride is a novel selective 5-HT 4 receptor
agonist that lacks a D2 receptor or K+ channel blocking
property [208]. Mosapride is shown to ameliorate delayed
gastric emptying [209]a sw e l la sc o n s t i p a t i o ni nP D[ 210],
byshorteningoftotalCTT(particularlythecaudalsegment),
and by augmenting the amplitude in rectal contraction
during defecation [210]. Improvement of parkinsonism
is more signiﬁcant with pergolide-mosapride than with
pergolide-domperidone [211]. Tegaserod, a selective 5-HT 4
agonist, is also eﬀective in ameliorating constipation in PD
[212].
3.4.6. Other Drugs. Although prior reports have indicated
the eﬀectiveness of motilides (erythromycin, etc.) [213],
neurotrophin-3 [214] and colchicine [215] on constipation
in PD, their use remains limited. Type A botulinum toxin
injection into the puborectalis muscle [216, 217]a n d
biofeedback [218] ameliorates anismus in PD.
4.SexualDysfunctioninPD
4.1. Neural Control of Erection: Normal Erection in Men.
S e x u a ld y s f u n c t i o ni sn o tu n c o m m o ni nP D[ 5, 219–
223]. Studies have shown that sexual dysfunction has great
signiﬁcance in relation to quality-of-life measures. However,
the detailed mechanism of sexual dysfunction in PD has not
been well known.
The genital organ primarily shares lumbosacral innerva-
tion with the lower urinary tract. Erection is a vascular event
[224]; occurring secondarily after dilatation of the cavernous
helical artery and compression of the cavernous vein to the
tunica albuginea [224]. Helical artery dilatation is brought
about by activation of cholinergic and nitrergic nerves; this
activation facilitates nitric oxide secretion from the vascular
endothelium. Ejaculation is brought about by contraction of
the vas deferens and the bladder neck, in order to prevent
retrograde ejaculation, by activation of adrenergic nerves
(Figure 6). Sexual intercourse in healthy men can be divided
into 3 phases [225]: (a) desire (libido), (b) excitement and
erection, and (c) orgasm, seminal emission from the vas
deferens, and ejaculation from the penis. Erection can be
further classiﬁed into 3 types by the relevant stimulation:
(1) psychogenic erection (by audiovisual stimulation), (2)
reﬂexive erection (by somatosensory stimulation), and (3)
nocturnalpeniletumescence(NPT;associatedwithrapideye
movement (REM-) sleep). “Morning erection” is considered
the last NPT in the nighttime.
4.2. Hypothalamic Neurons and Dopamine in Men. Among
t h e3t y p e so fe r e c t i o n ,r e ﬂ e x i v ee r e c t i o nr e q u i r e sa ni n t a c t
sacral cord, particularly the intermediolateral (IML) cell
columns. Pathology studies have shown that involvement of
the IML nucleus is common in MSA, whereas it is uncom-
m o ni nP D .T h e r e f o r e ,r e ﬂ e x i v ee r e c t i o nc a nb ea ﬀected in
patients with MSA. In patients with a supra-sacral spinal
cord lesion, reﬂexive erection might be preserved, whereas
psychogenic erection is severely disturbed because of a lesion
in the spinal pathways to the sacral cord. Libido and erection
arethoughttoberegulatedbythehypothalamus;particularly
the medial preoptic area (MPOA) and the paraventricular
nucleus (PVN) (Figure 4)[ 226, 227]. Electrical or chemical
stimulation in the MPOA/PVN evoked erection and mating
behaviors in experimental animals, both of which were
abolished by destruction of these areas. Somatosensory
inputs from the genitalia ascend in the anterior spinal cord,
and project to the MPOA/PVN via the thalamic nuclei.
Erotic visual inputs from the retina are thought to reach theParkinson’s Disease 11
A6: LC (noradrenergic)
Pontine erection centre?
Thoracic cord
T12-L2
S2-4
/vas deferens
IML(cholinergic)
to the penis
to the BC muscle
A10: VTA
A9: SNC (dopaminergic)
Medial frontal 
cortex
Caudate nucleus
(Cerebellum)
Ch5,6: LDTN/PBN
(cholinergic) DVN (cholinergic)
(Glutamergic)
(GABAergic)
MPOA
PVN
putamen
ZI
Autoonmic 
neural network
Ch4: NBM 
(cholinergic) 
PAG
TR
(HCNergic)
Cavenous/helical artery
NA
Higher centre 
/psychogenic 
erection
Pons 
/nocturnal
erection
Spinal
cord
/reﬂexive
erection
mACh/NO
nACh
Onuf’s nucleus
IML (α-adrenergic)
to the internal sphincter
Figure 6: Neural circuitry relevant to erection. PAG, periaqueductal gray; LC, locus coeruleus; NBM, nucleus basalis Meynert; PVN,
paraventricular nucleus; MPOA, medial preoptic area; A, adrenergic/noradrenergic; ZI, zona incerta; VTA, ventral tegmental area; SNC,
substantia nigra pars compacta; DLTN, dorsolateral tegmental nucleus; PBN, parabrachial nucleus; IML, intermediolateral nucleus; GABA,
γ-aminobutyric acid; T, thoracic; L, lumbar; S, sacral; NA, noradrenaline; Ach, acetylcholine; NO, nitric oxide. See text.
MPOA via the mamillary body. Recent neuroimaging studies
haveshownthatpenilestimulationorwatchingpornography
activatedtheseareasinhumans[228].NPT[229]seemstobe
regulated by the hypothalamic lateral preoptic area [230].
The raphe nucleus and the locus ceruleus are candidate
areas participating in the regulation of NPT. Oxytocinergic
neurons in the hypothalamic PVN are thought to facilitate
erection by projecting directly to the sacral cord, and by
projecting to the midbrain periaqueductal gray and the
Barrington’s nucleus (identical to the PMC). Serum oxytocin
concentrationincreasesduringmasturbationinhealthymen.
In experimental animals, dopamine is known to facilitate
erection and mating behaviors. The MPOA/PVN receives
projections from the nigral dopaminergic neurons [231]. A
microdialysisstudyshowedthatthedopamineconcentration
in the MPOA was increased by sexual stimulation. It is
reported that dopamine D1/D2 receptors in the hypotha-
lamus participate in erection whereas only D2 receptors
participate in ejaculation. Pathology studies have shown
that the hypothalamus is aﬀected in PD [231]. Recently,
polymorphism in the dopamine D4 receptor gene is shown
to contribute to individual diﬀerences in human sexual
behavior [232]. Prolactinergic neurons are thought to be
inhibitory in sexual function. Serum prolactin levels increase
after orgasm in healthy men. Prolactin-producing pituitary
tumors often cause gynecomastia and erectile dysfunc-
tion in male patients. Hyperprolactinemia occurs after the
use of sulpiride, metoclopramide, and chlorpromazine (all
dopamine receptor antagonists). Therefore, dopaminergic
neurons seem to facilitate oxytocinergic neurons whereas
they inhibit prolactinergic neurons. Some de novo PD
patients have hyper prolactinemia [233], which may con-
tribute to erectile dysfunction in those patients.
4.3. Female Sexual Function and Dopamine. As compared
with male genitalia, studies of female genital organs are
limited. Vulva [234], clitoris [235] and vagina [236]p r i m a r -
ily shares lumbosacral innervation with the lower urinary
tract. Sexual arousal in women is a vasocongestive and neu-
romuscular event through these organs, paralleling genital
lubrication, controlled by facilitatory parasympathetic (by
vasoactive intestinal peptide, nitric oxide, and to a lesser
extent acetylcholine, via the pelvic nerves from S2–4 inter-
mediolateral (IML) cell column) and inhibitory sympathetic
(by noradrenaline, via the hypogastric nerves from T12-
L3 IML cell column,) inputs. Some information is thought
to travel the vagal nerves. Activity of these spinal nuclei
is controlled by sensory aﬀerents from the genitalia and
descending projections from the brain.
Like men, libido in women is thought to be regulated
by the hypothalamus. The neural circuit for lordosis in
animalsinvolvesasupraspinalloop,whichiscontrolledbyan
estrogen- and progesterone-dependent signal, presumably
at the ventromedial hypothalamus (VMH), medial preoptic
area (MPOA), and paraventricular nucleus (PVN) in the
hypothalamus.Lordosisisfacilitatedbylutenizinghormone-
releasing factor (LHRH), alpha-melanocyte stimulating hor-
mone (alpha-MSH), and methionine-enkephalin whereas
suppressed by corticotrophin-releasing factor and beta-
endorphin [237, 238]. Recent neuroimaging studies have
shown that vaginal self-stimulation with/without orgasm12 Parkinson’s Disease
activated these areas in humans [239]. Oxytocinergic neu-
rons in the VMH and the MPOA are thought to facilitate
vagino-clitorial sexual arousal and lordosis by projecting
directly to the sacral cord [238, 240]. Role of dopamine in
female sexual function remains not completely clear [241].
It is reported that lordosis was increased in female animals
by microinjection of apomorphine (D1, 2 agonist) and
quinpirole (D2 agonist) in the MPOA whereas it decreased
by SKF 38393 (D1 agonist) [242]. This was counteracted by
chemical inhibition of dopaminergic neurons in the ventral
tegmental area (VTA) [243].
4.3.1. Male Sexual Symptoms. The reported prevalence of
sexual symptoms in men with PD ranges from 37% to
65% [234–239] .O n l yf e wp r e v i o u ss t u d i e sh a v el o o k e da t
sexual symptoms in PD and control subjects. Jacobs et
al. [244] studied 121 men with PD (mean age 45 years)
and 126 age- and sex-matched community male controls.
Patients were more dissatisﬁed with their present sexual
functioning and relationship whereas no diﬀerences were
found for the frequency of sexual intercourse itself. Erection
and ejaculation were not inquired. Sakakibara et al. [5]
analyzedsexualfunctionof46menwithPD(age35–70years
old) and 258 healthy male control subjects (age 30–70 years
old) [5]. As compared with the control group, the frequency
of dysfunction in PD patients was signiﬁcantly higher for
decrease of libido (84%), decrease of sexual intercourse
(55%), decrease of orgasm (87%), and decrease of erection
(79%) and ejaculation (79%). Therefore, sexual dysfunction
is signiﬁcant in PD. The majority of patients had onset of
the sexual dysfunction after the appearance of the motor
disorder. This is in contrast to patients with MSA, who often
have sexual dysfunction before the onset of motor disorder.
Comparing the results between four age subgroups
(subjects in their 30s, 40s, 50s, and 60s) in the control
group, the frequencies of sexual intercourse and of orgasm
were signiﬁcantly lower in older individuals [5]. In the PD
group, only the frequency of orgasm was lower in older
men (P<0.05). Comparing the results between both
sexes in the control group, decrease of libido and orgasm
were more common in women (P<0.01). In the PD
group, there was no signiﬁcant diﬀerence in sexual function
items. Bronner et al. [245] reported that use of medications
(selective serotonin reuptake inhibitors used for comorbid
depression), and advanced PD stage contributed to the
development of ED.
4.3.2. Rigiscan. In healthy men, sexual intercourse is thought
to be carried out by integrating aﬀective, motor, sensory,
autonomic, and other factors. In male patients with PD,
depression, motor disorder, and pain inevitably lead to
sexual dysfunction. In contrast, it has been diﬃcult to
determine to what extent autonomic factors contribute to
the sexual dysfunction in PD. However, erectile dysfunction
often precedes motor disorder in MSA, and abnormal NPT
is not uncommon in PD. These ﬁndings strongly suggest that
the disorder does in fact contribute to sexual dysfunction in
PD. Rigiscan is an objective measure for erectile dysfunction,
which allows both tumescence and rigidity measurement,
and is suitable for assessing NPT.
Only few data have been available concerning the rela-
tionship between NPT and dopamine. However, in experi-
mental animals, administration of levodopa elicited erection
and yawning together. Animals with experimental parkin-
sonism showed fewer REM stages during sleep than control
animals did.
4.3.3. Female Sexual Dysfunction. As compared with men,
few studies are available concerning female sexual dysfunc-
tion in PD. Further, only few previous studies have looked
at female sexual symptoms in PD and control subjects.
Sakakibara et al. [5] analyzed sexual function of 38 women
with PD(age35–70 yearsold) and98 healthycontrolwomen
(age 30–70 years old) [5]. As compared with the control
group, the frequency of dysfunction in women with PD was
signiﬁcantly higher fordecrease of libido (83%) and decrease
of sexual intercourse (88%) while decrease of orgasm was
not diﬀerent between women with PD and control. The
majority of patients had onset of the sexual dysfunction
after the appearance of the motor disorder. Welsh et al.
[246] studied 27 women with PD (mean age 67 years)
and community healthy controls, and in both group 50%
were sexually active. As compared with control, women
with PD had more common decrease of libido, vaginal
tightness,involuntaryurination,anddissatisfactioninsexual
intercourse. There was no diﬀerence in terms of sexual
arousal, sexual intercourse, and orgasm. Without control, in
young PD patients (36–56 years) women had more common
sexual problems (decrease of libido, 70%, decrease of sexual
intercourse, 80%) than men (40%, 33.4%, resp.) [247, 248].
Other domains, such as loss of lubrication and pain, are not
clearly known.
4.4. Treatment of Sexual Dysfunction in PD
4.4.1. Male Sexual Dysfunction
Dopaminergic Drugs. It is possible that levodopa and other
antiparkinson medication may aﬀect sexual function in PD.
However,itisnotentirelycleartowhatextentlevodopaame-
liorates sexual dysfunction in PD. In contrast, subcutaneous
apomorphine injection is used to ameliorate ﬂuctuating
symptoms in PD. It has also been used to treat erectile
dysfunction in the general population [247, 248] and in
patients with PD [249], although the dose is diﬀerent (gen-
eral population, initial 2mg and up to 3mg [247, 248], PD,
4mg[250]).Apomorphineisthoughttostimulatedopamine
D2receptors,andactivateoxytocinergicneuronsinthePVN.
Nausea is a common side eﬀect of this drug. Cabergoline
[251]andpergolide[252]arealsoreportedtoimprovesexual
dysfunction in PD. In contrast, pathological hypersexuality
may occur together with [253] or without delirium [254],
which is attributed to the dopamine dysregulation syndrome
in this disorder. DBS in the STN has produced either
improved sexual wellbeing [255] or transient mania with
hypersexuality [256] in patients with PD.Parkinson’s Disease 13
Phosphodiesterase-5 Inhibitors. When dopaminergic drugs
did not help, phosphodiesterase-5 inhibitors, for example,
sildenaﬁl, vardenaﬁl, and so forth, become the ﬁrst line
treatment in PD [257, 258]. These drugs inhibit nitric oxide
degradation and facilitate smooth muscle relaxation in the
cavernous tissue. When treating PD patients with postural
hypotension, these drugs should be prescribed with extreme
caution [258].
Other Drugs. When phosphodiesterase-5 inhibitors did not
help, recent trials of melanocortin, for example, melanotan-
II, bremelanotide, and so forth, showed that these drugs
might become a choice for treating erectile dysfunction.
A group of pro-opio-melanocortin (POMC) gene prod-
ucts include adrenocorticotropic hormone (ACTH), α-
melanocyte stimulating hormone (α-MSH), β-MSH, and γ-
MSH. It is known that the arcuate nucleus of the hypotha-
lamus projects POMC-containing neurons to the lateral
hypothalamus,dorsalmedialnucleus,MPOA,andPVN[22].
α-MSHassecretedintheMPOAandPVNparticipatesinthe
central control of sexual function [21] .B r e m e l a n o t i d ei sa
melanocortin receptor agonist, and is reported to be eﬀective
for treating erectile dysfunction as compared with placebo
[259].
4.4.2. Female Sexual Dysfunction. There is no established
regimen to treat sexual dysfunction in women with PD.
PDE5 inhibitors, such as sildenaﬁl, tadalaﬁl, and vardenaﬁl,
has become the ﬁrst choice in the treatment of erectile
dysfunction in men. Whereas sildenaﬁl facilitated clitorial
engorgement in women with sexual dysfunction [260],
clinical eﬃcacy of this drug in women with PD awaits
further clariﬁcation [261]. Bremelanotide, a melanocortin
receptor agonist, is applied to female sexual dysfunction, and
is reported to be eﬀective [262].
5. Conclusions
This article reviewed the current concepts of bladder, bowel,
and sexual dysfunction (pelvic organ dysfunctions) in PD.
Central nervous system pathology is clearly associated with
bladder (urinary urgency/frequency) and sexual dysfunction
(decrease in libido, erection, and overall dissatisfaction) in
PD. In contrast, both central (weak strain and anismus)
and peripheral myenteric pathology (slow colonic transit
and loss of rectal contraction) are associated with bowel
dysfunction. Anticholinergic agents are generally used to
treat bladder dysfunction while phosphodiesterase inhibitors
are used to treat sexual dysfunction. Dietary ﬁbers, laxatives,
and serotonergic agents are used to treat bowel dysfunction.
These treatments are beneﬁcial in maximizing patients’
quality of life.
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